Los Angeles, CA – October 2, 2025 - The Terasaki Institute for Biomedical Innovation (TIBI) announces a leadership transition as Dr. Ali Khademhosseini concluded his tenure as Chief Executive Officer and Executive Director. He is pursuing entrepreneurial ventures at the intersection of artificial intelligence and biomedical innovation. We wish Dr. Khademhosseini well in his future endeavors.
To ensure continuity and progress, Dr. Xiling Shen has been appointed as Acting Director to oversee TIBI’s research programs and guide our scientific vision. Dr. Shen’s leadership, supported by the Board of Directors, will ensure that the Institute’s mission continues without interruption.
TIBI remains firmly committed to advancing biomedical innovation to improve human health. Our research programs, collaborations and partnerships remain strong, and we are focused on the opportunities ahead as we enter this next chapter.
We thank our staff, partners and community for their ongoing support and dedication to the mission of the Terasaki Institute. Together, we will continue to build on the Terasaki legacy and drive the next generation of biomedical breakthroughs.